TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants – past, present and future

Carswell, 1975, An endotoxin-induced serum factor that causes necrosis of tumors, Proc Natl Acad Sci U S A, 72, 3666, 10.1073/pnas.72.9.3666 Green, 1982, Murine tumor necrosis-inducing factor: purification and effects on myelomonocytic leukemia cells, J Natl Cancer Inst, 68, 997 Matthews, 1980, Tumour-necrosis factor from the rabbit. IV. Purification and chemical characterization, Br J Cancer, 42, 416, 10.1038/bjc.1980.253 Ruff, 1980, Purification and physico-chemical characterization of rabbit tumor necrosis factor, J Immunol, 125, 1671, 10.4049/jimmunol.125.4.1671 Matthews, 1979, Tumour-necrosis factor from the rabbit. III. Relationship to interferons, Br J Cancer, 40, 534, 10.1038/bjc.1979.218 Prince, 1982, Inhibition of L-cell growth in agarose (ILGA): a simple inexpensive method for the detection and quantitation of factors inhibiting tumor cell growth, J Immunol Methods, 48, 367, 10.1016/0022-1759(82)90337-4 Bloksma, 1983, Antitumour activity of endotoxin, concanavalin A and poly I: C and their ability to elicit tumour necrosis factor, cytostatic factors, and interferon in vivo, Cancer Immunol Immunother, 16, 35, 10.1007/BF00199903 Williamson, 1983, Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon, Proc Natl Acad Sci U S A, 80, 5397, 10.1073/pnas.80.17.5397 English, 1991, Differential regulation of lymphotoxin and tumor necrosis factor genes in human T lymphocytes, J Biol Chem, 266, 7108, 10.1016/S0021-9258(20)89617-3 Kelker, 1985, Characterization of human tumor necrosis factor produced by peripheral blood monocytes and its separation from lymphotoxin, Int J Cancer, 36, 69, 10.1002/ijc.2910360112 Turner, 1988, Comparison of patterns of expression of tumour necrosis factor, lymphotoxin and interleukin-6 mRNA, Biochem Biophys Res Commun, 153, 1144, 10.1016/S0006-291X(88)81347-0 Fransen, 1985, Molecular cloning of mouse tumour necrosis factor cDNA and its eukaryotic expression, Nucleic Acids Res, 13, 4417, 10.1093/nar/13.12.4417 Shirai, 1985, Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor, Nature, 313, 803, 10.1038/313803a0 Wang, 1985, Molecular cloning of the complementary DNA for human tumor necrosis factor, Science, 228, 149, 10.1126/science.3856324 Haranaka, 1984, Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice, Int J Cancer, 34, 263, 10.1002/ijc.2910340219 Ziegler-Heitbrock, 1986, Tumor necrosis factor as effector molecule in monocyte mediated cytotoxicity, Cancer Res, 46, 5947 Haranaka, 1987, Antitumour effects of tumour necrosis factor: cytotoxic or necrotizing activity and its mechanism, Ciba Found Symp, 131, 140 Creaven, 1987, Phase I clinical trial of recombinant human tumor necrosis factor, Cancer Chemother Pharmacol, 20, 137, 10.1007/BF00253968 Feinberg, 1988, A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients, J Clin Oncol, 6, 1328, 10.1200/JCO.1988.6.8.1328 Schwartz, 1989, A phase I trial of recombinant tumor necrosis factor (rTNF) administered by continuous intravenous infusion in patients with disseminated malignancy, Biotherapy, 1, 207, 10.1007/BF02170889 Zamkoff, 1989, A phase I trial of subcutaneously administered recombination tumor necrosis factor to patients with advanced malignancy, J Biol Response Mod, 8, 539 Negrier, 1991, Phase I trial of recombinant interleukin-2 followed by recombinant tumor necrosis factor in patients with metastatic cancer, J Immunother, 11, 93, 10.1097/00002371-199202000-00003 Roberts, 2011, Systemic use of tumor necrosis factor-α as an anticancer agent, Oncotarget, 2, 739, 10.18632/oncotarget.344 Beutler, 1985, Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin, Science, 4716 Shalaby, 1989, Endotoxin, tumor necrosis factor-α and interleukin 1 induce interleukin 6 production in vivo, Clin Immunol Immunopathol, 53, 488, 10.1016/0090-1229(89)90010-X Zhang, 1988, Enhancement of cAMP levels and of protein kinase activity by tumor necrosis factor and interleukin 1 in human fibroblasts: role in the induction of interleukin 6, Proc Natl Acad Sci U S A, 85, 6802, 10.1073/pnas.85.18.6802 Falvo, 2010, Transcriptional control of the TNF gene, Curr Dir Autoimmun, 11, 27, 10.1159/000289196 Tsai, 1996, Cell-type-specific regulation of the human tumor necrosis factor-α gene in B cells and T cells by NFATp and ATF-2/JUN, Mol Cell Biol, 16, 5232, 10.1128/MCB.16.10.5232 Tuohy, 1998, The epitope spreading cascade during progression of experimental autoimmune encephalomyelitis and multiple sclerosis, Immunol Rev, 164, 93, 10.1111/j.1600-065X.1998.tb01211.x Stamou, 2010, Posttranscriptional regulation of TNF mRNA: a paradigm of signal-dependent mRNA utilization and its relevance to pathology, Curr Dir Autoimmun, 11, 61, 10.1159/000289197 Zhang, 2002, AU-rich element-mediated translational control: complexity and multiple activities of trans-activating factors, Biochem Soc Trans, 30, 952, 10.1042/bst0300952 Black, 1995, A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells, Nature, 385, 729, 10.1038/385729a0 Moss, 1997, Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha, Nature, 385, 733, 10.1038/385733a0 Tartaglia, 1991, The two different receptors for tumor necrosis factor mediate distinct cellular responses, Proc Natl Acad Sci U S A, 88, 9292, 10.1073/pnas.88.20.9292 Grell, 1995, The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor, Cell, 83, 793, 10.1016/0092-8674(95)90192-2 Carpentier, 2004, Function and regulation of tumor necrosis factor type 2, Curr Med Chem, 11, 2205, 10.2174/0929867043364694 Aggarwal, 1985, Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon, Nature, 318, 665, 10.1038/318665a0 Tsujimoto, 1986, Interferon-gamma enhances expression of cellular receptors for tumor necrosis factor, J Immunol, 136, 2441, 10.4049/jimmunol.136.7.2441 Tartaglia, 1993, Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor, J Biol Chem, 268, 18542, 10.1016/S0021-9258(17)46661-0 Eissner, 2004, Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system, Cytokine Growth Factor Rev, 15, 353, 10.1016/j.cytogfr.2004.03.011 Watts, 1999, A casein kinase I motif present in the cytoplasmic domain of members of the tumour necrosis factor ligand family is implicated in ‘reverse signalling’, EMBO J, 18, 2119, 10.1093/emboj/18.8.2119 Xin, 2006, Dual regulation of soluble tumor necrosis factor-alpha induced activation of human monocytic cells via modulating transmembrane TNFα-mediated ‘reverse signaling’, Int J Mol Med, 18, 885 Zhang, 2008, Transmembrane TNF-alpha mediates “forward” and “reverse” signaling, inducing cell death or survival via the NF-κB pathway in Raji Burkitt lymphoma cells, J Leukoc Biol, 84, 789, 10.1189/jlb.0208078 Higuchi, 1997, Membrane tumor necrosis factor-alpha (TNF-alpha) expressed on HTLV-I-infected T cells mediates a costimulatory signal for B cell activation-characterization of membrane TNF-α, Clin Immunol Immunopathol, 82, 133, 10.1006/clin.1996.4291 Parry, 1997, Contact with T cells modulates monocyte IL-10 production: role of T cell membrane TNF-alpha, J Immunol, 158, 3673, 10.4049/jimmunol.158.8.3673 Xin, 2006, Dual regulation of soluble tumor necrosis factor-alpha induced activation of human monocytic cells via modulating transmembrane TNF-alpha-mediated ‘reverse signaling’, Int J Mol Med, 18, 885 Eissner, 2000, Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages, J Immunol, 164, 6193, 10.4049/jimmunol.164.12.6193 Hayder, 1999, Adenovirus-induced liver pathology is mediated through TNF receptors I and II but is independent of TNF or lymphotoxin, J Immunol, 163, 1516, 10.4049/jimmunol.163.3.1516 Ruddle, 2014, Lymphotoxin and TNF: how it all began-A tribute to the travelers, Cytokine Growth Factor Rev, 25, 83, 10.1016/j.cytogfr.2014.02.001 Chan, 2000, A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling, Science, 288, 2351, 10.1126/science.288.5475.2351 Tartaglia, 1993, Tumor necrosis factor's cytotoxic activity is signaled by the p55 TNF receptor, Cell, 73, 213, 10.1016/0092-8674(93)90222-C Jiang, 1999, Prevention of constitutive TNF receptor 1 signaling by silencer of death domains, Science, 283, 543, 10.1126/science.283.5401.543 Takada, 2003, Role of SODD in regulation of tumor necrosis factor responses, Mol Cell Biol, 23, 4026, 10.1128/MCB.23.11.4026-4033.2003 Hsu, 1996, TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways, Cell, 84, 299, 10.1016/S0092-8674(00)80984-8 Hsu, 1995, The TNF receptor-1 associated protein TRADD signals cell death and NF-κB activation, Cell, 81, 495, 10.1016/0092-8674(95)90070-5 Rothe, 1995, TRAF2 mediated activation of NF-κB by TNF receptor-2 and CD40, Science, 269, 1424, 10.1126/science.7544915 Rothe, 1994, A novel family of putative signal transducers associated with the cytoplasmic domain of the 75kDa tumour necrosis factor receptor, Cell, 78, 681, 10.1016/0092-8674(94)90532-0 Boldin, 1996, Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death, Cell, 85, 803, 10.1016/S0092-8674(00)81265-9 Ho, 2005, Mammalian initiator apoptotic caspases, FEBS J, 272, 5436, 10.1111/j.1742-4658.2005.04966.x Enari, 1998, A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD, Nature, 391, 43, 10.1038/34112 Muzio, 1996, Flice, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/Apo-1) death-inducing signalling complex, Cell, 85, 817, 10.1016/S0092-8674(00)81266-0 Vince, 2009, TRAF2 must bind to cellular inhibitors of apoptosis for tumor necrosis factor (TNF) to efficiently activate NF-κB and to prevent TNF-induced apoptosis, J Biol Chem, 284, 35906, 10.1074/jbc.M109.072256 Wang, 1998, NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation, Science, 281, 1680, 10.1126/science.281.5383.1680 Darzynkiewicz, 1984, Cell cycle-specific effects of tumor necrosis factor, Cancer Res, 44, 83 Austgulen, 1986, Role of monocyte cytotoxic factor in cytolysis of actinomycin D-treated WEHI 164 cells mediated by freshly isolated human adherent mononuclear blood cells, Cancer Res, 46, 4566 Munker, 1987, In vitro action of tumor necrosis factor on myeloid leukemia cells, Blood, 69, 1102, 10.1182/blood.V69.4.1102.1102 Suyama, 1985, Effects of murine tumor necrosis factor on friend erythroleukemic cells, Exp Cell Biol, 53, 85 Sedger, 1999, IFN-γ mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression, J Immunol, 163, 920, 10.4049/jimmunol.163.2.920 Wong, 1992, Antiviral activity of tumour necrosis factor is signaled through the 55-kDa type I TNF receptor, J Immunol, 149, 3350, 10.4049/jimmunol.149.10.3350 Mak, 2002, Signaling for survival and apoptosis in the immune system, Arthritis Res, 4, S243, 10.1186/ar569 Natoli, 1997, Activation of SAPK/JNK by TNF receptor 1 through a noncytotoxic TRAF2-dependent pathway, Science, 275, 200, 10.1126/science.275.5297.200 Song, 1997, Tumor necrosis factor (TNF)- mediated kinase cascades: bifurcation of nuclear factor-κB and c-jun N-terminal kinase (JNK/SAPK) pathways at TNF receptor-associated factor 2, Proc Natl Acad Sci U S A, 94, 9792, 10.1073/pnas.94.18.9792 Shikama, 2004, Caspase-8 and caspase-10 activate NF-κB through RIP, NIK and IKKα kinases, Eur J Immunol, 33, 1998, 10.1002/eji.200324013 Zuckerman, 1991, Transcriptional and post-transcriptional mechanisms involved in the differential expression of LPS-induced IL-1 and TNF mRNA, Immunology, 73, 460 Gupta, 1995, Transcription factor ATF2 regulation by the JNK signal transduction pathway, Science, 267, 389, 10.1126/science.7824938 Westwick, 1994, Tumor necrosis factor alpha stimulates AP-1 activity through prolonged activation of the c-Jun kinase, J Biol Chem, 269, 26396, 10.1016/S0021-9258(18)47207-9 Kohase, 1986, Induction of beta 2-interferon by tumor necrosis factor: a homeostatic mechanism in the control of cell proliferation, Cell, 45, 659, 10.1016/0092-8674(86)90780-4 Fransen, 1986, Recombinant tumor necrosis factor: its effect and its synergism with interferon-γ on a variety of normal and transformed human cell lines, Eur J Cancer Clin Oncol, 22, 419, 10.1016/0277-5379(86)90107-0 Zarnegar, 2008, Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK, Nat Immunol, 9, 1371, 10.1038/ni.1676 Liao, 2004, Regulation of the NF-κB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation, J Biol Chem, 279, 26243, 10.1074/jbc.M403286200 Qing, 2005, Stabilization of basally translated NF-κB-inducing kinase (NIK) protein functions as a molecular switch of processing of NF-κB2 p100, J Biol Chem, 280, 40578, 10.1074/jbc.M508776200 Razani, 2010, Negative feedback in noncanonical NF-kappaB signaling modulates NIK stability through IKKα-mediated phosphorylation, Sci Signal, 3, ra41, 10.1126/scisignal.2000778 McPherson, 2012, Opposing roles for TRAF1 in the alternative versus classical NF-κB pathway in T cells, J Biol Chem, 287, 23010, 10.1074/jbc.M112.350538 Michel, 2014, Activation-induced tumor necrosis factor receptor-associated factor 3 (Traf3) alternative splicing controls the noncanonical nuclear factor κB pathway and chemokine expression in human T cells, J Biol Chem, 289, 13651, 10.1074/jbc.M113.526269 Xie, 2011, TNF receptor-associated factor 3 is required for T cell-mediated immunity and TCR/CD28 signaling, J Immunol, 186, 143, 10.4049/jimmunol.1000290 Gerlach, 2011, Linear ubiquitination prevents inflammation and regulates immune signalling, Nature, 471, 591, 10.1038/nature09816 Haas, 1999, Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction, Mol Cell, 36, 831, 10.1016/j.molcel.2009.10.013 Ikeda, 2011, SHARPIN forms a linear ubiquitin ligase complex regulating NF-κB activity and apoptosis, Nature, 471, 637, 10.1038/nature09814 Tokunaga, 2011, SHARPIN is a component of the NF-κB-activating linear ubiquitin chain assembly complex, Nature, 471, 633, 10.1038/nature09815 Tokunaga, 2009, Involvement of linear polyubiquitylation of NEMO in NF-κB activation, Nat Cell Biol, 11, 123, 10.1038/ncb1821 Chaudhary, 2000, Activation of the NF-κB pathway by caspase 8 and its homologs, Oncogene, 19, 4451, 10.1038/sj.onc.1203812 Kataoka, 2004, N-terminal fragment of c-FLIP(L) processed by caspase 8 specifically interacts with TRAF2 and induces activation of the NF-κB signaling pathway, Mol Cell Biol, 24, 2627, 10.1128/MCB.24.7.2627-2636.2004 Matsuda, 2014, J Biol Chem, 289, 3876, 10.1074/jbc.M113.506485 Deng, 2003, A JNK-dependent pathway is required for TNFα-induced apoptosis, Cell, 115, 61, 10.1016/S0092-8674(03)00757-8 Schwabe, 2004, Differential requirement for c-Jun NH2-terminal kinase in TNFα-Fas-mediated apoptosis in hepatocytes, FASEB J, 18, 720, 10.1096/fj.03-0771fje Ruby, 1997, Antiviral activity of tumor necrosis factor (TNF) is mediated via p55 and p75 TNF receptors, J Exp Med, 186, 1591, 10.1084/jem.186.9.1591 Sedger, 2005, Viral inhibition of tumour necrosis factor-α and TNFα and TNF-receptor induced apoptosis and inflammation, Curr Med Chem Anti Inflam Anti Aller, 4, 597, 10.2174/156801405774933124 Hiscott, 2006, Manipulation of the nuclear factor-kappaB pathway and the innate immune response by viruses, Oncogene, 25, 6844, 10.1038/sj.onc.1209941 Mohamed, 2009, NFκB inhibitors: strategies from poxviruses, Cell Cycle, 8, 3125, 10.4161/cc.8.19.9683 Komiyama, 1994, Inhibition of interleukin-1 beta converting enzyme by the cowpox virus serpin CrmA. An example of cross-class inhibition, J Biol Chem, 269, 19331, 10.1016/S0021-9258(17)32171-3 Tewari, 1995, Fas- and tumor necrosis factor-induced apoptosis is inhibited by the poxvirus crmA gene product, J Biol Chem, 270, 3255, 10.1074/jbc.270.7.3255 Thome, 1997, Viral FLICE-inhibitory proteins (FLIPS) prevent apoptosis induced by death receptors, Nature, 386, 517, 10.1038/386517a0 Chan, 2003, A role for tumor necrosis factor receptor-2 and receptor-interacting protein in programmed necrosis and antiviral responses, J Biol Chem, 278, 51613, 10.1074/jbc.M305633200 Warzocha, 1995, Mechanisms of action of the tumor necrosis factor and lymphotoxin ligand-receptor system, Eur Cytokine Netw, 6, 83 Schütze, 1994, The role of diacylglycerol and ceramide in tumor necrosis factor and interleukin-1 signal transduction, J Leukoc Biol, 56, 533, 10.1002/jlb.56.5.533 Schütze, 1992, TNF activates NF-κB by phosphatidylcholine-specific phospholipase C-induced “acidic” sphingomyelin breakdown, Cell, 71, 765, 10.1016/0092-8674(92)90553-O Fiers, 1987, Structure-function relationship of tumour necrosis factor and its mechanism of action, Ciba Found Symp, 131, 109 Adam-Klages, 1996, FAN, a novel WD-repeat protein, couples the p55 TNF-receptor to neutral sphingomyelinase, Cell, 86, 937, 10.1016/S0092-8674(00)80169-5 Heinrich, 2004, Cathepsin D links TNF-induced acid sphingomyelinase to Bid-mediated caspase-9 and -3 activation, Cell Death Differ, 11, 550, 10.1038/sj.cdd.4401382 Heinrich, 2000, Ceramide as an activator lipid of cathepsin D, Adv Exp Med Biol, 477, 305, 10.1007/0-306-46826-3_33 Peppelenbosch, 1991, Multiple signal transduction pathways regulate TNF-induced actin reorganization in macrophages: inhibition of Cdc42-mediated filopodium formation by TNF, J Immunol, 162, 837, 10.4049/jimmunol.162.2.837 Boecke, 2012, Factor associated with neutral sphingomyelinase activity mediates navigational capacity of leukocytes responding to wounds and infection: live imaging studies in zebrafish larvae, J Immunol, 189, 1559, 10.4049/jimmunol.1102207 Nixon, 2009, Sphingolipids in inflammation: pathological implications and potential therapeutic targets, Br J Pharmacol, 158, 982, 10.1111/j.1476-5381.2009.00281.x Takeda, 1987, Identity of differentiation inducing factor and tumour necrosis factor, Nature, 323, 338, 10.1038/323338a0 Trinchieri, 1986, Tumor necrosis factor and lymphotoxin induce differentiation of human myeloid cell lines in synergy with immune interferon, J Exp Med, 164, 1206, 10.1084/jem.164.4.1206 Jelinek, 1987, Enhancement of human B cell proliferation and differentiation by tumor necrosis factor-α and interleukin 1, J Immunol, 139, 2970, 10.4049/jimmunol.139.9.2970 Kehrl, 1987, Effect of tumor necrosis factor-α on mitogen-activated human B cells, J Exp Med, 166, 786, 10.1084/jem.166.3.786 Palombella, 1988, Mitogenic action of tumor necrosis factor in human fibroblasts: interaction with epidermal growth factor and platelet-derived growth factor, J Cell Physiol, 135, 23, 10.1002/jcp.1041350104 Vilcek, 1986, Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors, J Exp Med, 163, 632, 10.1084/jem.163.3.632 Dinarello, 1986, Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1, J Exp Med, 164, 1443 Philip, 1986, Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, γ-interferon and interleukin-1, Nature, 323, 86, 10.1038/323086a0 Brouckaert, 1989, Circulating interleukin 6 during a continuous infusion of tumor necrosis factor and interferon-γ, J Exp Med, 169, 2257, 10.1084/jem.169.6.2257 Christoforidis, 2003, Isolated limb perfusion: distinct tourniquet and tumor necrosis factor effects on the early hemodynamic response, Arch Surg, 138, 17, 10.1001/archsurg.138.1.17 Waage, 1989, The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome, J Exp Med, 169, 333, 10.1084/jem.169.1.333 Waage, 1989, Local production of tumor necrosis factor alpha, interleukin 1, and interleukin 6 in meningococcal meningitis, relation to the inflammatory response, J Exp Med, 170, 1859, 10.1084/jem.170.6.1859 Dinarello, 1991, The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome, J Infect Dis, 163, 1177, 10.1093/infdis/163.6.1177 McDermott, 1999, Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes, Cell, 97, 133, 10.1016/S0092-8674(00)80721-7 Rebelo, 2006, Modeling of tumor necrosis factor receptor superfamily 1A mutants associated with tumor necrosis factor receptor-associated periodic syndrome indicates misfolding consistent with abnormal function, Arthritis Rheum, 54, 2674, 10.1002/art.21964 Todd, 2004, Mutant forms of tumour necrosis factor receptor I that occur in TNF-receptor-associated periodic syndrome retain signalling functions but show abnormal behaviour, Immunology, 113, 65, 10.1111/j.1365-2567.2004.01942.x Yousaf, 2005, Tumor necrosis factor receptor I from patients with tumor necrosis factor receptor-associated periodic syndrome interacts with wild-type tumor necrosis factor receptor I and induces ligand-independent NF-κB activation, Arthritis Rheum, 52, 2906, 10.1002/art.21268 Lobito, 2006, Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS), Blood, 108, 1320, 10.1182/blood-2005-11-006783 Bulua, 2011, Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS), J Exp Med, 208, 519, 10.1084/jem.20102049 Dickie, 2012, Involvement of X-box binding protein 1 and reactive oxygen species pathways in the pathogenesis of tumour necrosis factor receptor-associated periodic syndrome, Ann Rheum Dis, 71, 2035, 10.1136/annrheumdis-2011-201197 Kimberley, 2007, Falling into TRAPS – receptor misfolding in the TNF receptor 1-associated periodic fever syndrome, Arthritis Res Ther, 9, 217, 10.1186/ar2197 Savic, 2012, Autoinflammatory syndromes and cellular responses to stress: pathophysiology, diagnosis and new treatment perspectives, Best Pract Res Clin Rheumatol, 26, 505, 10.1016/j.berh.2012.07.009 Bulua, 2012, Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study, Arthritis Rheum, 64, 908, 10.1002/art.33416 Vaitla, 2011, Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab, Arthritis Rheum, 63, 1151, 10.1002/art.30215 Cantarini, 2012, Tumour necrosis factor receptor-associated periodic syndrome (TRAPS): state of the art and future perspectives, Autoimmun Rev, 12, 38, 10.1016/j.autrev.2012.07.020 Wong, 1986, Tumour necrosis factors α and β inhibit virus replication and synergize with interferons, Nature, 323, 819, 10.1038/323819a0 Yamaguchi, 1997, Contrasting effects of TGFβ1 and TNFα on the development of dendritic cells from progenitors in mouse bone marrow, Stem Cells, 15, 144, 10.1002/stem.150144 Takashiba, 1999, Differentiation of monocytes to macrophages primes cells for lipopolysaccharide stimulation via accumulation of cytoplasmic nuclear factor κB, Infect Immun, 67, 5573, 10.1128/IAI.67.11.5573-5578.1999 Harris, 2008, Tumor necrosis factor blockers influence macrophage responses to Mycobacterium tuberculosis, J Infect Dis, 198, 1842, 10.1086/593174 Zhou, 2014, Macrophage polarization and function with emphasis on the evolving roles of coordinated regulation of cellular signaling pathways, Cell Signal, 26, 192, 10.1016/j.cellsig.2013.11.004 Cohen, 2013, Extrinsic and intrinsic control of macrophage inflammatory responses, J Leukoc Biol, 94, 913, 10.1189/jlb.0413236 Aversa, 1997, The 26-kD transmembrane form of tumor necrosis factor-α on activated CD4+ T cell clones provides a costimulatory signal for human B cell activation, J Exp Med, 177, 1575, 10.1084/jem.177.6.1575 Upton, 1991, Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence, Virology, 184, 370, 10.1016/0042-6822(91)90853-4 Schreiber, 1994, The myxoma virus TNF-receptor homologue (T2) inhibits tumor necrosis factor-α in a species-specific fashion, Virology, 204, 692, 10.1006/viro.1994.1585 Schreiber, 1996, Myxoma virus T2 protein, a tumor necrosis factor (TNF) receptor homolog, is secreted as a monomer and dimer that each bind rabbit TNFα, but the dimer is a more potent TNF inhibitor, J Biol Chem, 271, 13333, 10.1074/jbc.271.23.13333 Schreiber, 1997, Distinct domains of M-T2, the myxoma virus tumor necrosis factor (TNF) receptor homolog, mediate extracellular TNF binding and intracellular apoptosis inhibition, J Virol, 71, 2171, 10.1128/JVI.71.3.2171-2181.1997 Sedger, 1996, M-T2: a poxvirus TNF receptor homologue with dual activities, Immunol Cell Biol, 74, 538, 10.1038/icb.1996.87 Skelly, 2013, A systematic analysis of the peripheral and CNS effects of systemic LPS, IL-1B, TNF-α and IL-6 challenges in C57BL/6 mice, PLoS One, 8, e69123, 10.1371/journal.pone.0069123 Thomson, 2014, Peripheral inflammation is associated with remote global gene expression changes in the brain, J Neuroinflammation, 11, 73, 10.1186/1742-2094-11-73 Clark, 2010, The roles of TNF in brain dysfunction and disease, Pharmacol Ther, 128, 519, 10.1016/j.pharmthera.2010.08.007 McCoy, 2008, TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease, J Neuroinflammation, 5, 45, 10.1186/1742-2094-5-45 Kogo, 2006, Involvement of TNF-α in glutamate-induced apoptosis in a differentiated neuronal cell line, Brain Res, 1122, 201, 10.1016/j.brainres.2006.09.006 Kisiswa, 2013, TNFα reverse signaling promotes sympathetic axon growth and target innervation, Nat Neurosci, 16, 865, 10.1038/nn.3430 Siegel, 1995, The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo, Cytokine, 7, 15, 10.1006/cyto.1995.1003 Scallon, 1995, Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions, Cytokine, 7, 251, 10.1006/cyto.1995.0029 Elliott, 1994, Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor-α (cA2) versus placebo in rheumatoid arthritis, Lancet, 344, 1105, 10.1016/S0140-6736(94)90628-9 den Broeder, 2002, Long term anti-tumour necrosis factor-α monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation, Ann Rheum Dis, 61, 311, 10.1136/ard.61.4.311 Weinblatt, 2003, Adalimumab, a fully human anti-tumor necrosis factor-α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial, Arthritis Rheum, 48, 35, 10.1002/art.10697 van de Putte, 2004, Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed, Ann Rheum Dis, 63, 508, 10.1136/ard.2003.013052 Klareskog, 2004, Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial, Lancet, 363, 675, 10.1016/S0140-6736(04)15640-7 Lethaby, 2013, Etanercept for the treatment of rheumatoid arthritis, Cochrane Database Syst Rev, 5, CD004525 van der Heijde, 2006, Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial, Arthritis Rheum, 54, 1063, 10.1002/art.21655 Weinblatt, 1999, A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate, N Engl J Med, 340, 253, 10.1056/NEJM199901283400401 Hutas, 2010, Golimumab as the first monthly subcutaneous fully human anti-TNF-α antibody in the treatment of inflammatory arthropathies, Immunotherapy, 2, 453, 10.2217/imt.10.34 Smolen, 2009, Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor-α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial, Lancet, 374, 210, 10.1016/S0140-6736(09)60506-7 Oldfield, 2009, Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, BioDrugs, 23, 125, 10.2165/00063030-200923020-00005 Chapman, 2002, PEGylated antibodies and antibody fragments for improved therapy: a review, Adv Drug Deliv Rev, 54, 531, 10.1016/S0169-409X(02)00026-1 Bourne, 2008, A PEGylated Fab’ fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action, BioDrugs, 22, 331, 10.2165/00063030-200822050-00005 Sandborn, 2007, Certolizumab pegol for the treatment of Crohn's disease, N Engl J Med, 357, 228, 10.1056/NEJMoa067594 Schreiber, 2007, Maintenance therapy with certolizumab pegol for Crohn's disease, N Engl J Med, 357, 239, 10.1056/NEJMoa062897 Geiler, 2011, Anti-TNF treatment in rheumatiod athritis, Curr Pharm Des, 17, 3141, 10.2174/138161211798157658 Meroni, 2014, Tumour necrosis factor-α antagonists in the treatment of Rheumatoid arthritis: an immunological perspective, BioDrugs, 28, S5, 10.1007/s40259-013-0063-0 Edwards, 1999, PEGylated recombinat human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-R1): novel high affinity TNF receptor desgined for chonic inflammatory diseases, Ann Rheum Dis, 58, I73, 10.1136/ard.58.2008.i73 Bendele, 1999, Effects of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) alone and in combination with methotrexate in adjuvant arthritic rats, Clin Exp Rheumatol, 17, 553 McComb, 1999, Antiarthritic activity of soluble tumor necrosis factor receptor type I forms in adjuvant arthritis: correlation of plasma levels with efficacy, J Rheumatol, 26, 1347 Trinchard-Lugan, 2001, Safety, pharmakinetics and pharmacodynamics of recombinant human tumour necrosis factor binding proteins-1 (Onercept) injected by intravenous, intramuscular and subcutaneous routes into healthy volunteers, Eur Cytokine Netw, 12, 391 Kay, 2013, Biosimilars to treat inflammatory arthritis: the challenge of proving identity, Ann Rheum Dis, 72, 1589, 10.1136/annrheumdis-2012-203198 Scheinberg, 2012, The advent of biosimilar therapies in rheumatology-“O brave new world”, Nat Rev Rheumatol, 8, 430, 10.1038/nrrheum.2012.84 Yoo, 2013, A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study, Ann Rheum Dis, 72, 1613, 10.1136/annrheumdis-2012-203090 Park, 2013, A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study, Ann Rheum Dis, 72, 1605, 10.1136/annrheumdis-2012-203091 Aggarwal, 2009, Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets, Trends Pharmacol Sci, 30, 85, 10.1016/j.tips.2008.11.002 Fürst, 2014, Plant-derived anti-inflammatory compounds: hopes and disappointments regarding the translation of preclinical knowledge into clinical progress, Mediat Inflamm, 2014, 146832, 10.1155/2014/146832 Anand, 2007, Bioavailability of curcumin: problems and promises, Mol Pharm, 4, 807, 10.1021/mp700113r Sharma, 2007, Pharmacokinetics and pharmacodynamics of curcumin, Adv Exp Med Biol, 595, 453, 10.1007/978-0-387-46401-5_20 Doggui, 2012, Neuronal uptake and neuroprotective effect of curcumin-loaded PLGA nanoparticles on the human SK-N-SH cell line, J Alzheimers Dis, 20, 377, 10.3233/JAD-2012-112141 Ray, 2011, Neuroprotective and neurorescue effects of a novel polymeric nanoparticle formulation of curcumin (NanoCurc™) in the neuronal cell culture and animal model: implications for Alzheimer's disease, J Alzheimers Dis, 23, 61, 10.3233/JAD-2010-101374 Monroy, 2013, Curcumin and neurodegenerative diseases, Biofactors, 39, 122, 10.1002/biof.1063 Somers, 1960, Pharmacological properties of thalidomide (alpha-phthalimido glutarimide), a new sedative hypnotic drug, Br J Pharmacol Chemother, 15, 111, 10.1111/j.1476-5381.1960.tb01217.x Leck, 1962, Incidence of malformations since the introduction of thalidomide, Br Med J, 2, 16, 10.1136/bmj.2.5296.16 Majumdar, 2002, Thalidomide suppresses NF-κB activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester, J Immunol, 168, 2644, 10.4049/jimmunol.168.6.2644 Majumder, 2012, TNF α signaling beholds thalidomide saga: a review of mechanistic role of TNF-α signaling under thalidomide, Curr Top Med Chem, 12, 1456, 10.2174/156802612801784443 Zhou, 2013, Thalidomide-a notorious sedative to a wonder anticancer drug, Curr Med Chem, 20, 4102, 10.2174/09298673113209990198 Tweedie, 2012, Tumor necrosis factor-α synthesis inhibitor 3,6′-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer's disease, J Neuroinflamm, 9, 106, 10.1186/1742-2094-9-106 He, 2013, Long-term treatment of thalidomide ameliorates amyloid-like pathology through inhibition of β-secretase in a mouse model of Alzheimer's disease, PLoS One, 8, e55091, 10.1371/journal.pone.0055091 Kirchner, 2004, Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes, Cytokine, 28, 67, 10.1016/j.cyto.2004.06.008 Mitoma, 2005, Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-α, Gastroenterology, 128, 376, 10.1053/j.gastro.2004.11.060 Ringheanu, 2004, Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn's disease, Inflamm Bowel Dis, 10, 801, 10.1097/00054725-200411000-00015 Xin, 2006, Dual regulation of soluble tumour necrosis factor-α inducing activation of human monocytic cells via modulation transmembrane TNFα-metiated “reverse signalling”, Int J Mol Med, 18, 885 Marotte, 2014, Etanercept – TNF receptor and IgG1 Fc fusion protein: is it different from other TNF blockers?, Expert Opin Biol Ther, 14, 569, 10.1517/14712598.2014.896334 Rutgeerts, 1999, Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease, Gastroenterology, 117, 761, 10.1016/S0016-5085(99)70332-X Sandborn, 2001, Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial, Gastroenterology, 121, 5, 10.1053/gast.2001.28674 Mitoma, 2005, Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-α, Gastroenterology, 128, 376, 10.1053/j.gastro.2004.11.060 Taylor, 2010, Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases, Curr Opin Pharmacol, 10, 308, 10.1016/j.coph.2010.01.005 Di Sabatino, 2004, Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease, Gut, 53, 70, 10.1136/gut.53.1.70 Van den Brande, 2003, Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease, Gastroenterology, 124, 1774, 10.1016/S0016-5085(03)00382-2 Vos, 2011, Anti-tumor necrosis factor-α antibodies induce regulatory macrophages in an Fc region-dependent manner, Gastroenterology, 140, 221, 10.1053/j.gastro.2010.10.008 Nesbitt, 2007, Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents, Inflamm Bowel Dis, 13, 1323, 10.1002/ibd.20225 Furst, 2006, Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection, Semin Arthritis Rheum, 36, 159, 10.1016/j.semarthrit.2006.02.001 Nestorov, 2005, Clinical pharmacokinetics of TNF antagonists: how do they differ?, Semin Arthritis Rheum, 34, 12, 10.1016/j.semarthrit.2005.01.004 Feagan, 2005, A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-α in patients with corticosteroid-dependent Crohn's disease, Aliment Pharmacol Ther, 21, 373, 10.1111/j.1365-2036.2005.02336.x Sandborn, 2004, CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial, Gut, 53, 1485, 10.1136/gut.2003.035253 Chen, 2007, Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells, J Immunol, 179, 154, 10.4049/jimmunol.179.1.154 Nie, 2013, Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNFα in rheumatoid arthritis, Nat Med, 19, 322, 10.1038/nm.3085 Singh, 1995, Activation of transcription factor NF-κB is suppressed by curcumin (diferuloylmethane), J Biol Chem, 270, 24995, 10.1074/jbc.270.42.24995 Kim, 2005, Curcumin inhibits immunostimulatory function of dendritic cells: MAPKs and translocation of NF-κB as potential targets, J Immunol, 174, 8116, 10.4049/jimmunol.174.12.8116 Zhong, 2012, Curcumin inhibits ox-LDL-induced MCP-1 expression by suppressing the p38MAPK and NF-κB pathways in rat vascular smooth muscle cells, Inflamm Res, 61, 61, 10.1007/s00011-011-0389-3 Hong, 2004, Modulation of arachidonic acid metabolism by curcumin and related beta-diketone derivatives: effects on cytosolic phospholipase A(2), cyclooxygenases and 5-lipoxygenase, Carcinogenesis, 25, 1671, 10.1093/carcin/bgh165 Kang, 2004, Curcumin suppresses lipopolysaccharide-induced cyclooxygenase-2 expression by inhibiting activator protein 1 and nuclear factor κB bindings in BV2 microglial cells, J Pharmacol Sci, 94, 325, 10.1254/jphs.94.325 Karlstetter, 2011, Curcumin is a potent modulator of microglial gene expression and migration, J Neuroinflamm, 8, 125, 10.1186/1742-2094-8-125 Zhong, 2014, Curcumin suppresses tumor necrosis factor-α-induced matrix metalloproteinase-2 expression and activity in rat vascular smooth muscle cells via the NF-κB pathway, Exp Ther Med, 7, 1653, 10.3892/etm.2014.1647 Baert, 2003, Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease, N Engl J Med, 348, 601, 10.1056/NEJMoa020888 van Schouwenburg, 2013, Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation, Ann Rheum Dis, 72, 104, 10.1136/annrheumdis-2012-201445 Nanda, 2013, Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis, Am J Gastroenterol, 108, 40, 10.1038/ajg.2012.363 Steenholdt, 2012, Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease, J Crohns Colitis, 6, 108, 10.1016/j.crohns.2011.08.001 Garcês, 2013, The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis, Ann Rheum Dis, 72, 1947, 10.1136/annrheumdis-2012-202220 van Schouwenburg, 2013, Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis, Nat Rev Rheumatol, 9, 164, 10.1038/nrrheum.2013.4 Ma, 2013, Varicella zoster meningitis complicating combined anti-tumor necrosis factor and corticosteroid therapy in Crohn's disease, World J Gastroenterol, 19, 3347, 10.3748/wjg.v19.i21.3347 Lawrance, 2010, Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-α therapy: an Australian and New Zealand experience, J Gastroenterol Hepatol, 25, 1732, 10.1111/j.1440-1746.2010.06407.x Tresch, 2009, Disseminated herpes zoster mimicking rheumatoid vasculitis in a rheumatoid arthritis patient on etanercept, Dermatology, 219, 347, 10.1159/000232389 Bracaglia, 2012, Safety and efficacy of etanercept in a cohort of patients with juvenile idiopathic arthritis under 4 years of age, J Rheumatol, 39, 1287, 10.3899/jrheum.111555 Li Gobbi, 2005, Pneumonitis caused by Legionella pneumoniae in a patient with rheumatoid arthritis treated with anti-TNF-alpha therapy (infliximab), J Clin Rheumatol, 11, 119, 10.1097/01.rhu.0000158527.20518.30 Mancini, 2007, Tuberculosis and Legionella pneumophila pneumonia in a patient receiving anti-tumour necrosis factor-α (anti-TNF-alpha) treatment, Clin Microbiol Infect, 13, 1036, 10.1111/j.1469-0691.2007.01796.x Lanternier, 2013, Incidence and risk factors of Legionella pneumophila pneumonia during anti-tumor necrosis factor therapy: a prospective French study, Chest, 144, 990, 10.1378/chest.12-2820 Hofmann, 2009, Fulminant legionellosis in two patients treated with infliximab for Crohn's disease: case series and literature review, Can J Gastroenterol, 23, 829, 10.1155/2009/836938 Kang, 2007, Adenoviral pneumonia during etanercept treatment in a patient with rheumatoid arthritis, Korean J Intern Med, 22, 63, 10.3904/kjim.2007.22.1.63 Ahmad, 2007, Severe adenoviral pneumonia (AVP) following infliximan infusion for the treatment of Crohn's disease, J Infect Dis, 54, e29 Smith, 2002, Viral pneumonia as a serious complication of etanercept therapy, Ann Intern Med, 136, 174, 10.7326/0003-4819-136-2-200201150-00020 Kobie, 2011, Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor, Arthritis Res Ther, 13, R209, 10.1186/ar3542 Salemi, 2010, Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFα blockers: safety and immunogenicity, Clin Immunol, 134, 113, 10.1016/j.clim.2009.09.014 Cantini, 2014, Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance, J Rheumatol Suppl, 91, 47, 10.3899/jrheum.140102 Tubach, 2009, Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry, Arthritis Rheum, 60, 1884, 10.1002/art.24632 Harris, 2010, How tumour necrosis factor blockers interfere with tuberculosis immunity, Clin Exp Immunol, 161, 1, 10.1111/j.1365-2249.2010.04146.x Navarra, 2014, Risk of tuberculosis with anti-tumour necrosis factor-α therapy: substantially higher number of patients at risk in Asia, Int J Rheum Dis, 17, 3, 10.1111/1756-185X.12188 Kim, 2010, Tumor necrosis factor blockade and the risk of viral infection, Nat Rev Rheumatol, 6, 165, 10.1038/nrrheum.2009.279 Kelsen, 2011, Infliximab induces clonal expansion of γδ-T cells in Crohn's disease: a predictor of lymphoma risk?, PLoS One, 6, e17890, 10.1371/journal.pone.0017890 Tripodo, 2009, Gamma-delta T-cell lymphomas, Nat Rev Clin Oncol, 6, 707, 10.1038/nrclinonc.2009.169 Wong, 2012, Risk of lymphoma in patients receiving antitumor necrosis factor therapy: a meta-analysis of published randomized controlled studies, Clin Rheumatol, 31, 631, 10.1007/s10067-011-1895-y Campo, 2011, The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications, Blood, 117, 5019, 10.1182/blood-2011-01-293050 Singh, 2011, Adverse effects of biologics: a network meta-analysis and Cochrane overview, Cochrane Database Syst Rev, 2, 10.1002/14651858.CD008794.pub2 Kaplan, 1998, Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice, Proc Natl Acad Sci U S A, 95, 7556, 10.1073/pnas.95.13.7556 Kuprash, 2008, Ablation of TNF or lymphotoxin signaling and the frequency of spontaneous tumors in p53-deficient mice, Cancer Lett, 268, 70, 10.1016/j.canlet.2008.03.023 Smyth, 1998, An essential role for tumor necrosis factor in natural killer cell-mediated tumor rejection in the peritoneum, J Exp Med, 188, 1611, 10.1084/jem.188.9.1611 Glenn, 2012, Epstein–Barr virus, human papillomavirus and mouse mammary tumour virus as multiple viruses in breast cancer, PLoS One, 7, e48788, 10.1371/journal.pone.0048788 Heng, 2009, Human papilloma virus is associated with breast cancer, Br J Cancer, 101, 1345, 10.1038/sj.bjc.6605282 Kan, 2005, Identification of human papillomavirus DNA gene sequences in human breast cancer, Br J Cancer, 93, 946, 10.1038/sj.bjc.6602778 Mohan, 2001, Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides, Arthritis Rheum, 44, 2862, 10.1002/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W Solomon, 2011, Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors, Mult Scler, 17, 1472, 10.1177/1352458511412996 Tanno, 2006, New-onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients, Clin Rheumatol, 25, 929, 10.1007/s10067-005-0097-x Fromont, 2009, Inflammatory demyelinating events following treatment with anti-tumor necrosis factor, Cytokine, 45, 55, 10.1016/j.cyto.2008.11.002 Magnano, 2004, Demyelination and inhibition of tumor necrosis factor (TNF), Clin Exp Rheumatol, 22, S134 Andreadou, 2013, Demyelinating disease following anti-TNFα treatment: a causal or coincidental association? Report of four cases and review of the literature, Case Rep Neurol Med, 2013, 671935 Kaltsonoudis, 2014, Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study, Arthritis Res Ther, 16, R125, 10.1186/ar4582 Kaltsonoudis, 2014, Demyelination and other neurological adverse events after anti-TNF therapy, Autoimmun Rev, 13, 54, 10.1016/j.autrev.2013.09.002 Chung, 2003, Circulation, 107, 3133, 10.1161/01.CIR.0000077913.60364.D2 Kwon, 2003, Case reports of heart failure after therapy with a tumor necrosis factor antagonist, Ann Intern Med, 138, 807, 10.7326/0003-4819-138-10-200305200-00008 Ding, 2010, BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies, Rheumatology (Oxford), 49, 2217, 10.1093/rheumatology/keq249a Ledingham, 2005, British thoracic society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-{alpha} treatments, Rheumatology (Oxford), 44, 1205, 10.1093/rheumatology/kei103 van Breukelen-van der Stoep, 2013, Cardiovascular risk in rheumatoid arthritis: how to lower the risk?, Atherosclerosis, 231, 163, 10.1016/j.atherosclerosis.2013.09.006 Sugamura, 2013, Reactive oxygen species in cardiovascular disease, Free Radic Biol Med, 51, 978, 10.1016/j.freeradbiomed.2011.05.004 Listing, 2008, Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?, Arthritis Rheum, 58, 667, 10.1002/art.23281 Barbhaiya, 2013, Rheumatoid arthritis and cardiovascular disease: an update on treatment issues, Curr Opin Rheumatol, 25, 317, 10.1097/BOR.0b013e32835fd7f8 van Zeben, 1993, Factors predicting outcome of rheumatoid arthritis: results of a followup study, J Rheumatol, 20, 1288 Sokolove, 2011, Immune complexes containing citrullinated fibrinogen costimulate macrophages via Toll-like receptor 4 and Fcγ receptor, Arthritis Rheum, 63, 53, 10.1002/art.30081 Emery, 2011, Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response, Ann Rheum Dis, 70, 2063, 10.1136/ard.2010.148015 Dejaco, 2010, Third generation anti-cyclic citrullinated peptide antibodies do not predict anti-TNF-α treatment response in rheumatoid arthritis, Rheumatol Int, 30, 451, 10.1007/s00296-009-0978-4 Lv, 2014, The status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-TNFα agent treatment in patients with rheumatoid arthritis: a meta-analysis, PLoS One, 9, e89422, 10.1371/journal.pone.0089442 Hueber, 2009, Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis, Arthritis Res Ther, 11, R76, 10.1186/ar2706 Coulthard, 2013, Differential effects of infliximab on absolute circulating blood leucocyte counts of innate immune cells in early and late rheumatoid arthritis patients, Clin Exp Immunol, 170, 36, 10.1111/j.1365-2249.2012.04626.x Lucherini, 2013, First report of circulating microRNAs in tumour necrosis factor receptor-associated periodic syndrome (TRAPS), PLoS One, 8, e73443, 10.1371/journal.pone.0073443 Sandborn, 2013, A special meeting review edition: clinical research highlights in ibd: diagnosis and anti-tumor necrosis factor monitoring, Gastroenterol Hepatol, 9, 1 Billioud, 2011, Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review, Am J Gastroenterol, 106, 674, 10.1038/ajg.2011.60 Molnár, 2012, Frequency and predictors of loss of response to infliximab or adalimumab in Crohn's disease after one-year treatment period – a single center experience, J Gastrointestin Liver Dis, 21, 265 Baert, 2013, Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients, J Crohns Colitis, 7, 154, 10.1016/j.crohns.2012.03.018 Atreya, 2014, In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease, Nat Med, 20, 313, 10.1038/nm.3462 Wilson, 1997, Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation, Proc Natl Acad Sci U S A, 94, 3195, 10.1073/pnas.94.7.3195 Plant, 2011, Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci, Arthritis Rheum, 63, 645, 10.1002/art.30130 Márquez, 2014, Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-analysis, Arthritis Res Ther, 16, R66, 10.1186/ar4504 Krintel, 2012, Investigation of single nucleotide polymorphisms and biological pathways associated with response to TNFα inhibitors in patients with rheumatoid arthritis, Pharmacogenet Genomics, 22, 577, 10.1097/FPC.0b013e3283544043 Sode, 2014, Anti-TNF treatment response in rheumatoid arthritis patients is associated with genetic variation in the NLRP3-inflammasome, PLoS One, 9, e100361, 10.1371/journal.pone.0100361 Umiċeviċ Mirkov, 2013, Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis, Ann Rheum Dis, 72, 1375, 10.1136/annrheumdis-2012-202405 Thomas, 2014, Association of rs1568885, rs1813443 and rs4411591 polymorphisms with anti-TNF medication response in Greek patients with Crohn's disease, World J Gastroenterol, 20, 3609, 10.3748/wjg.v20.i13.3609 Scardapane, 2012, TNF-α polymorphisms in juvenile idiopathic arthritis: which potential clinical implications?, Int J Rheumatol, 2012, 756291, 10.1155/2012/756291 Mathews, 2014, Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment, Ann Rheum Dis, 73, 1202, 10.1136/annrheumdis-2013-203276 Martinon, 2004, Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases, Cell, 117, 561, 10.1016/j.cell.2004.05.004 Pétrilli, 2007, The inflammasome: a danger sensing complex triggering innate immunity, Curr Opin Immunol, 19, 615, 10.1016/j.coi.2007.09.002 Schoultz, 2009, Combined polymorphisms in genes encoding the inflammasome components NALP3 and CARD8 confer susceptibility to Crohn's disease in Swedish men, Am J Gastroenterol, 104, 1180, 10.1038/ajg.2009.29 Coulthard, 2011, Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients, Ann Rheum Dis, 70, 98, 10.1136/ard.2010.133249 Vivar, 2014, Advances in the treatment of rheumatoid arthritis, F1000Prime Rep, 6, 31, 10.12703/P6-31 McInnes, 2013, Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial, Lancet, 382, 780, 10.1016/S0140-6736(13)60594-2 Ritchlin, 2014, Ann Rheum Dis, 73, 990, 10.1136/annrheumdis-2013-204655 Takasaki, 1997, Structure-based design and characterization of exocyclic peptidomimetics that inhibit TNFα binding to its receptor, Nat Biotechnol, 15, 15, 10.1038/nbt1197-1266 Sedger, 2006, Poxviral tumour necrosis factor receptor (TNFR)-like T2 proteins contain a concerved pre-ligand association domain (PLAD) that inhibits cellular TNFR2 induced cell death, J Virol, 80, 9300, 10.1128/JVI.02449-05 Cao, 2011, Expression and purification of a natural N-terminal pre-ligand assembly domain of tumor necrosis factor receptor 1 (TNFR1 PLAD) and preliminary activity determination, Protein J, 30, 281, 10.1007/s10930-011-9330-4 Deng, 2005, Amelioration of inflammatory arthritis by targetting the pre-ligand assembly domain of tumour necrosis factor receptors, Nat Med, 11, 1304, 10.1038/nm1304 Macen, 1996, Expression of the myxoma virus tumor necrosis factor receptor homologue and M11L genes is required to prevent virus-induced apoptosis in infected rabbit T lymphocytes, Virology, 218, 232, 10.1006/viro.1996.0183 Wang, 2011, Targeting pre-ligand assembly domain of TNFR1 ameliorates autoimmune diseases – an unrevealed role in downregulation of Th17 cells, J Autoimmun, 37, 160, 10.1016/j.jaut.2011.05.013 Carter, 2001, Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-alpha, Proc Natl Acad Sci U S A, 98, 11879, 10.1073/pnas.211178398 He, 2005, Small-molecule inhibition of TNF-alpha, Science, 310, 1022, 10.1126/science.1116304 Ma, 2014, A novel small-molecule tumor necrosis factor α inhibitor attenuates inflammation in a hepatitis mouse model, J Biol Chem, 289, 12457, 10.1074/jbc.M113.521708 Zhang, 2004, J Pharmacol Exp Ther, 309, 348, 10.1124/jpet.103.059675 Beck, 2002, (E)-2(R)-[1(S)-(hydroxycarbamoyl)-4-phenyl-3-butenyl]-2′-isobutyl-2′-(methanesulfonyl)-4-methylvalero hydrazide (Ro 32-7315), a selective and orally active inhibitor of tumor necrosis factor-α convertase, J Pharmacol Exp Ther, 302, 390, 10.1124/jpet.302.1.390 Conway, 2001, J Pharmacol Exp Ther, 298, 900 Coulthard, 2012, Differential effects of infliximab on absolute circulating blood leucocyte counts of innate immune cells in early and late rheumatoid arthritis patients, Clin Exp Immunol, 170, 36, 10.1111/j.1365-2249.2012.04626.x Cooper, 2012, FcγRIIIa expression on monocytes in rheumatoid arthritis: role in immune-complex stimulated TNF production and non-response to methotrexate therapy, PLoS One, 7, e28918, 10.1371/journal.pone.0028918 Getts, 2014, Therapeutic inflammatory monocyte modulation using immune-modifying microparticles, Sci Transl Med, 6, ra7, 10.1126/scitranslmed.3007563 Frankel, 2013, Targeting T cells to tumor cells using bispecific antibodies, Curr Opin Chem Biol, 17, 385, 10.1016/j.cbpa.2013.03.029 Heiss, 2010, The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial, Int J Cancer, 127, 2209, 10.1002/ijc.25423 Teachey, 2013, Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy, Blood, 121, 5154, 10.1182/blood-2013-02-485623 Vincent, 2012, Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates, Biotechnol J, 7, 1444, 10.1002/biot.201200250 Sockolosky, 2012, Engineering neonatal Fc receptor-mediated recycling and transcytosis in recombinant proteins by short terminal peptide extensions, Proc Natl Acad Sci U S A, 109, 16095, 10.1073/pnas.1208857109 Xiao, 2013, Receptor-mediated endocytosis and brain delivery of therapeutic biologics, Int J Cell Biol, 2013, 703545, 10.1155/2013/703545 Sumbria, 2012, Brain protection from stroke with intravenous TNFα decoy receptor-Trojan horse fusion protein, J Cereb Blood Flow Metab, 32, 1933, 10.1038/jcbfm.2012.97 Zhou, 2011, Neuroprotection with a brain-penetrating biologic tumor necrosis factor inhibitor, J Pharmacol Exp Ther, 339, 618, 10.1124/jpet.111.185876 Zaremba, 2001, Tumour necrosis factor-alpha is increased in the cerebrospinal fluid and serum of ischaemic stroke patients and correlates with the volume of evolving brain infarct, Biomed Pharmacother, 55, 258, 10.1016/S0753-3322(01)00058-0 Pandya, 2011, Focal cerebral ischemia and mitochondrial dysfunction in the TNFα-transgenic rat, Brain Res, 1384, 151, 10.1016/j.brainres.2011.01.102 Pettigrew, 2008, Focal cerebral ischemia in the TNFα-transgenic rat, J Neuroinflamm, 5, 47, 10.1186/1742-2094-5-47 Sumbria, 2013, Pharmacokinetics and brain uptake of an IgG-TNF decoy receptor fusion protein following intravenous, intraperitoneal, and subcutaneous administration in mice, Mol Pharm, 10, 1425, 10.1021/mp400004a Zou, 2013, Cell-penetrating peptide-mediated therapeutic molecule delivery into the central nervous system, Curr. Neuropharmacol., 11, 197, 10.2174/1570159X11311020006 Tobinick, 2010, Perispinal etanercept: a new theraeutic paradigm in neurology, Expert Rev Neurother, 10, 985, 10.1586/ern.10.52 Hess, 2011, Blockade of TNF-α rapidly inhibits pain responses in the central nervous system, Proc Natl Acad Sci U S A, 108, 3731, 10.1073/pnas.1011774108 Serratrice, 2007, Dramatic etanercept-induced remission of relapsing febrile sciatic neuralgia related to p46l mutation of the tnfrsf1a gene, Clin Rheumatol, 26, 1535, 10.1007/s10067-006-0418-8 Tobinick, 2010, Perispinal etanercept: a new therapeutic paradigm in neurology, Expert Rev Neurother, 10, 985, 10.1586/ern.10.52 Taylor, 2010, Patient perceptions concerning pain management in the treatment of rheumatoid arthritis, J Int Med Res, 38, 1213, 10.1177/147323001003800402 Andrade, 2012, The thalidomide analgesic effect is associated with differential TNF-α receptor expression in the dorsal horn of the spinal cord as studied in a rat model of neuropathic pain, Brain Res, 1450, 24, 10.1016/j.brainres.2012.02.033 Li, 2013, Curcumin attenuates diabetic neuropathic pain by downregulating TNFα in a rat model, Int J Med Sci, 10, 377, 10.7150/ijms.5224 Zhu, 2014, Curcumin alleviates neuropathic pain by inhibiting p300/CBP histone acetyltransferase activity-regulated expression of BDNF and cox-2 in a rat model, PLoS One, 9, e91303, 10.1371/journal.pone.0091303 George, 2000, Thalidomide treatment in chronic constrictive neuropathy decreases endoneurial tumor necrosis factor-alpha, increases interleukin-10 and has long-term effects on spinal cord dorsal horn met-enkephalin, Pain, 88, 267, 10.1016/S0304-3959(00)00333-X Raedler, 2011, Inflammatory mechanisms in major depressive disorder, Curr Opin Psychiatry, 6, 519, 10.1097/YCO.0b013e32834b9db6 Simen, 2006, TNFα signaling in depression and anxiety: behavioral consequences of individual receptor targeting, Biol Psychiatry, 59, 775, 10.1016/j.biopsych.2005.10.013 Kaster, 2012, Depressive-like behavior induced by tumor necrosis factor-α in mice, Neuropharmacology, 62, 419, 10.1016/j.neuropharm.2011.08.018 Himmerich, 2006, Successful antidepressant therapy restores the disturbed interplay between TNF-α system and HPA axis, Biol Psychiatry, 60, 882, 10.1016/j.biopsych.2006.03.075 Montgomery, 2011, Ablation of TNF-RI/RII expression in Alzheimer's disease mice leads to an unexpected enhancement of pathology: implications for chronic pan-TNFα suppressive therapeutic strategies in the brain, Am J Pathol, 179, 2053, 10.1016/j.ajpath.2011.07.001 Schabert, 2013, Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population, J Manag Care Pharm, 19, 621, 10.18553/jmcp.2013.19.8.621 Grover, 2012, Pharmaceutical companies and global lack of access to medicines: strengthening accountability under the right to health, J Law Med Ethics, 40, 234, 10.1111/j.1748-720X.2012.00661.x Taylor, 2009, Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis, Nat Rev Rheumatol, 5, 578, 10.1038/nrrheum.2009.181 Deighton, 2010, BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy, Rheumatology (Oxford), 49, 1197, 10.1093/rheumatology/keq006a Scott, 2009, NICE guidelines on anti-tumor necrosis factor therapy for RA, Nat Clin Pract Rheumatol, 5, 16, 10.1038/ncprheum0964 Feagan, 2006, CDP571, a humanized monoclonal antibody to tumour necrosis factor-α, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial, Aliment Pharmacol Ther, 23, 617, 10.1111/j.1365-2036.2006.02791.x Mamula, 2004, CDP571, a humanized anti-tumor necrosis factor-α monoclonal antibody in pediatric Crohn's disease, Inflamm Bowel Dis, 10, 723, 10.1097/00054725-200411000-00005 Glatt, 2005, Population pharmacokinetics of onercept in healthy subjects, Clin Pharmacokinet, 44, 1295, 10.2165/00003088-200544120-00008 Nikas, 2003, Onercept. Serono., Curr Opin Investig Drugs, 4, 1369 Rutgeerts, 2003, Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study, Aliment Pharmacol Ther, 17, 185, 10.1046/j.1365-2036.2003.01414.x Trinchard-Lugan, 2001, Safety, pharmacokinetics and pharmacodynamics of recombinant human tumour necrosis factor-binding protein-1 (Onercept) injected by intravenous, intramuscular and subcutaneous routes into healthy volunteers, Eur Cytokine Netw, 12, 391 Davis, 2000, Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type I: a clinical update, Ann Rheum Dis, 59, 41, 10.1136/ard.59.suppl_1.i41 Moreland, 2000, Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritis, J Rheumatol, 27, 601